HOME >> BIOLOGY >> NEWS
Biomedicines presents promising results from phase II trials of omega interferon for the treatment of hepatitis C

tectable in blood despite treatment with alpha interferon. Within 48 hours of the initiation of treatment with omega interferon, HCV RNA fell sharply in all patients, and in some to undetectable levels.

Chief Executive Officer Dr. Mark Moran said, "We are pleased with these results. We believe they also support our new drug delivery efforts with this drug. In collaboration with ALZA, we are also putting omega interferon into the implantable DUROS delivery system. With DUROS, we hope to be able to deliver omega interferon for months with a single administration.

Hepatitis C infection can lead to severe impairment of liver function, liver fibrosis, and liver cancer. According to the U.S. Center for Disease Control, HCV infects nearly 3 million people in the United States, and the World Health Organization estimates 170 million people are infected worldwide. Many infected persons are unaware of the infection. The spread of HCV infection has reached epidemic proportions, as some experts believe that without substantial improvements in treatment, the death toll from HCV infection will surpass that from HIV.


'"/>

Contact: Emily Katz
e.katz@noonanrusso.com
415-677-4455
Noonan/Russo Communications
12-Nov-2001


Page: 1 2

Related biology news :

1. DFG presents the 2004 MAK and BAT value lists
2. VIB presents its annual results at BIO2004 in San Francisco
3. Steroid-coated DNA represents new approach to gene delivery
4. ASH presents advocacy awards to Sen. Dianne Feinstein and Claude Lenfant, M.D.
5. DFG presents the new MAK and BAT Value List 2003
6. Center for Health Law and Policy presents program on bioterrorism measures and civil liberties
7. Agriculture presents common ground for rural, urban people
8. UPCI presents study on estrogenic activity of medicinal botanicals
9. UPCI presents study on dendritic cells in prostate cancer
10. UPCI presents study on discovery of protein that suppresses dendritic cells
11. USF presents new research on hyperlipidemic children

Post Your Comments:
(Date:4/22/2014)... Consortium Ltd.,s nanotechnology expert will present a poster ... at the 7th International Nanotoxicology Congress to ... , Dr. Monita Sharma will outline a strategy consistent ... of Sciences, " Toxicity Testing in the 21st Century: ... of non-animal methods involving human cells and cell lines ...
(Date:4/22/2014)... presented Beaumont Health System with prestigious, competitive research ... athletic and nonathletic injuries. , The American ... grant to fund stem cell-based research that could ... ruptured knee anterior cruciate ligament, or ACL. According ... cruciate ligament injury is the over-stretching or tearing ...
(Date:4/22/2014)... at the University of Kentucky has discovered new methods ... , The research, led by Peixuan Guo, professor ... the UK College of Pharmacy and Markey Cancer Center, ... Boiling-Resistant Anionic Polymer Material To Build Robust Structures with ... and Daniel L. Jasinski. , The article, which will ...
Breaking Biology News(10 mins):Beaumont awarded grants to study sports-related injury treatment, improve recovery 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s resolutions ... care of my furry companion." Nowadays there are pet salons, dog ... to take the little canine or feline darlings along wherever mommy ... some pricey toys at the pet store. But anyone who has ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
Cached News: